Quebec reimburses once-yearly osteoporosis treatment
This article was originally published in Scrip
Executive Summary
Novartis' once-yearly osteoporosis treatment Aclasta (zoledronic acid 5mg/100ml), for the treatment of postmenopausal osteoporosis (PMO) in women who cannot receive an oral bisphosphonate, has been reimbursed in Quebec, Canada since October 1st.